What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Sell
36
TNXP Quote, Financials, Valuation and Earnings
Last price:
$33.97
Seasonality move
:
-15.89%
Day range:
$33.30 - $36.20
52-week range:
$6.76 - $137.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.84x
P/B ratio:
1.31x
Volume:
508.5K
Avg. volume:
1.1M
1-year change:
-72.81%
Market cap:
$237M
Revenue:
$10.1M
EPS (TTM):
-$1,963.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$2.6M | -$3.09 | 15.49% | -99.42% | $61.67 |
|
ABBV
AbbVie
|
$12.9B | $2.40 | 3.24% | 313.38% | $208.86 |
|
BIVI
BioVie
|
-- | -$0.32 | -- | -38.46% | $6.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$32.36 | $61.67 | $237M | -- | $0.00 | 0% | 8.84x |
|
ABBV
AbbVie
|
$185.39 | $208.86 | $327.5B | 78.89x | $1.64 | 3.44% | 5.73x |
|
BIVI
BioVie
|
$1.03 | $6.00 | $19.1M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.58 | $0.85 | $3.4M | -- | $0.00 | 0% | 0.16x |
|
OGEN
Oragenics
|
$3.61 | $1.00 | $2.6M | -- | $0.00 | 0% | 1.16x |
|
TOVX
Theriva Biologics
|
$0.43 | $7.00 | $3.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
-- | -3.184 | -- | 11.24x |
|
ABBV
AbbVie
|
98.01% | -0.472 | 18.88% | 0.48x |
|
BIVI
BioVie
|
-- | 0.691 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$1.5M | -$15.1M | -114.25% | -121.16% | -622.93% | -$16.6M |
|
ABBV
AbbVie
|
$9.3B | $4B | 5.54% | 81.41% | 17.7% | $1.4B |
|
BIVI
BioVie
|
-- | -$3M | -- | -- | -- | -$1.3M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Tonix Pharmaceuticals Holding vs. Competitors
-
Which has Higher Returns TNXP or ABBV?
AbbVie has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of 9.64%. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat AbbVie's return on equity of 81.41%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M ABBVAbbVie70.01% $0.72 $71.4B -
What do Analysts Say About TNXP or ABBV?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 90.57%. On the other hand AbbVie has an analysts' consensus of $208.86 which suggests that it could grow by 12.66%. Given that Tonix Pharmaceuticals Holding has higher upside potential than AbbVie, analysts believe Tonix Pharmaceuticals Holding is more attractive than AbbVie.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 ABBVAbbVie12 12 0 -
Is TNXP or ABBV More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison AbbVie has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.205%.
-
Which is a Better Dividend Stock TNXP or ABBV?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie offers a yield of 3.44% to investors and pays a quarterly dividend of $1.64 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. AbbVie pays out 257.71% of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or ABBV?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are smaller than AbbVie quarterly revenues of $13.3B. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than AbbVie's net income of $1.3B. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while AbbVie's PE ratio is 78.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 8.84x versus 5.73x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding8.84x -- $2.4M -$16.8M ABBVAbbVie5.73x 78.89x $13.3B $1.3B
-
Which has Higher Returns TNXP or BIVI?
BioVie has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat BioVie's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M BIVIBioVie-- -$0.15 -- -
What do Analysts Say About TNXP or BIVI?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 90.57%. On the other hand BioVie has an analysts' consensus of $6.00 which suggests that it could grow by 482.52%. Given that BioVie has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe BioVie is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 BIVIBioVie1 0 0 -
Is TNXP or BIVI More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison BioVie has a beta of 1.232, suggesting its more volatile than the S&P 500 by 23.154%.
-
Which is a Better Dividend Stock TNXP or BIVI?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioVie offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. BioVie pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or BIVI?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than BioVie quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than BioVie's net income of -$2.8M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while BioVie's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 8.84x versus -- for BioVie. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding8.84x -- $2.4M -$16.8M BIVIBioVie-- -- -- -$2.8M
-
Which has Higher Returns TNXP or NBY?
NovaBay Pharmaceuticals has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of -49.65%. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About TNXP or NBY?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 90.57%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 47.24%. Given that Tonix Pharmaceuticals Holding has higher upside potential than NovaBay Pharmaceuticals, analysts believe Tonix Pharmaceuticals Holding is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is TNXP or NBY More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock TNXP or NBY?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or NBY?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 8.84x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding8.84x -- $2.4M -$16.8M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns TNXP or OGEN?
Oragenics has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M OGENOragenics-- -$3.60 -- -
What do Analysts Say About TNXP or OGEN?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 90.57%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 731.11%. Given that Oragenics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Oragenics is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 OGENOragenics0 1 0 -
Is TNXP or OGEN More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock TNXP or OGEN?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or OGEN?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Oragenics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Oragenics's net income of -$2.2M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 8.84x versus 1.16x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding8.84x -- $2.4M -$16.8M OGENOragenics1.16x -- -- -$2.2M
-
Which has Higher Returns TNXP or TOVX?
Theriva Biologics has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About TNXP or TOVX?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 90.57%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1519.25%. Given that Theriva Biologics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Theriva Biologics is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 TOVXTheriva Biologics1 1 0 -
Is TNXP or TOVX More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock TNXP or TOVX?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or TOVX?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Theriva Biologics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Theriva Biologics's net income of -$4.3M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 8.84x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding8.84x -- $2.4M -$16.8M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NuScale the Best Nuclear Stock to Buy?
NuScale Power (NYSE:SMR) is a nuclear power startup that has…
Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 50x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
76
AVAV alert for Jun 26
AeroVironment [AVAV] is up 21.6% over the past day.
Buy
51
SITM alert for Jun 26
SiTime [SITM] is down 15.62% over the past day.
Buy
54
NGVC alert for Jun 26
Natural Grocers by Vitamin Cottage [NGVC] is down 12.33% over the past day.
